Targeted therapies are designed to work against specific vulnerabilities in a cancer cell.

The targeted therapy drug venetoclax is designed to block the function of the B-cell lymphoma-2 (Bcl-2) protein, which normally works to prevent cell death.

Venetoclax was first approved in 2016 for treating certain patients with chronic lymphocytic leukemia, which has high levels of Bcl-2. More recently, venetoclax has begun to show...